Jim Simons acquired 1.99 Million Neurocrine Biosciences shares worth $266 Million. That's 0.41% of their equity portfolio (38th largest holding). The investor owns 2.02% of the outstanding Neurocrine Biosciences stock. The first Neurocrine Biosciences trade was made in Q3 2015. Since then Jim Simons bought shares twelve more times and sold shares on thirteen occasions. The stake costed the investor $214 Million, netting the investor a gain of 24% so far.